Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 9/20 | 0.68 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.51 |
| ▸ | METAP1 | P53582 | 2/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12269444 | 0.99 | ACHE (0.67) | ACHECYP19A1SIGMAR1METAP1HDAC1 | |
| Hydrochloric Acid SCHEMBL2332692 | 0.97 | ACHE (0.66) | ACHECYP19A1SIGMAR1METAP1HDAC1 | |
| SCHEMBL3033688 | 0.86 | CYP19A1 (0.77) | ACHECYP19A1SIGMAR1METAP1HDAC1 | |
| Bromide SCHEMBL2331283 | 0.83 | ACHE (0.76) | ACHECYP19A1METAP1 | |
| Bromide SCHEMBL2403927 | 0.83 | ACHE (0.76) | ACHECYP19A1METAP1 | |
| Bromide SCHEMBL2403769 | 0.81 | ACHE (1.00) | ACHE | |
| Hydrochloric Acid SCHEMBL2329151 | 0.81 | ACHE (0.74) | ACHECYP19A1METAP1 | |
| Hydrochloric Acid SCHEMBL2338476 | 0.81 | ACHE (0.74) | ACHECYP19A1METAP1 | |
| SCHEMBL7895132 | 0.80 | ACHE (1.00) | ACHE | |
| Bromide SCHEMBL2404741 | 0.80 | ACHE (0.72) | ACHECYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220265685-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY | 2022-08-25 | — | — | US | disclosed |
| US-11160785-B2 | Methods and compositions for improving cognitive function | AGENEBIO INC. (US) | 2021-11-02 | — | — | US | disclosed |
| US-20180015109-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY | 2018-01-18 | — | — | US | disclosed |
| US-20160271108-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | AGENEBIO, INC. | 2016-09-22 | — | — | US | disclosed |
| EP-2533645-B1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | UNIV JOHNS HOPKINS (US) | 2016-07-27 | — | — | EP | disclosed |
| EP-2533645-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | The Johns Hopkins University (US) | 2012-12-19 | — | — | EP | disclosed |
| US-20110212928-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-09-01 | — | — | US | disclosed |
| WO-2011100373-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-08-18 | — | — | WO | disclosed |
| EP-1047674-B1 | PROCESS FOR PRODUCTION OF DONEPEZIL DERIVATIVES | EISAI CO LTD (JP) | 2005-03-30 | — | — | EP | disclosed |
| US-6706741-B2 | ALZHEIMER*S DISEASE | EISAI CO., LTD. (JP) | 2004-03-16 | — | — | US | disclosed |
| US-20030069289-A1 | Acetylcholinesterase inhibitors containing 1-benzyl-pyridinium salts | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2003-04-10 | — | — | US | disclosed |
| EP-1285656-A1 | ACETYLCHOLINESTERASE INHIBITORS CONTAINING 1-BENZYL- PYRIDINIUM SALTS | Eisai Co., Ltd. (JP) | 2003-02-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160271108-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | BACE2, BACE1, GRIN2A | ACHE 4/4885CYP19A1 2172/4885SIGMAR1 2391/4885 |
| US-20030069289-A1 | Acetylcholinesterase inhibitors containing 1-benzyl-pyridinium salts | ACHE, CHRM1, BCHE | ACHE 1/4885CYP19A1 1333/4885SIGMAR1 221/4885 |
| US-11160785-B2 | Methods and compositions for improving cognitive function | BACE2, BACE1, GRIN2A | ACHE 4/4885CYP19A1 2172/4885SIGMAR1 2391/4885 |
| US-20180015109-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | BACE1, BACE2, ACHE | ACHE 3/4885CYP19A1 2161/4885SIGMAR1 3684/4885 |
| US-20220265685-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | BACE1, BACE2, ACHE | ACHE 3/4885CYP19A1 2161/4885SIGMAR1 3684/4885 |
| US-20110212928-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | BACE1, BACE2, ACHE | ACHE 3/4885CYP19A1 2161/4885SIGMAR1 3684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.